SUMMIT Partner Akeso Reports 8.2-Month Survival Edge Over Keytruda
Ivonescimab cut the risk of death 27% versus pembrolizumab in Akeso's Chinese Phase III HARMONi-2 trial, with median overall survival of 30.8 months.
Read more
TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.